Comparative Pharmacology
Head-to-head clinical analysis: AMBENYL versus ANTITUSSIVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBENYL versus ANTITUSSIVE.
AMBENYL vs ANTITUSSIVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Each 5 mL contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL per day.
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
None Documented
None Documented
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
Category C
Category C
Antitussive/Antihistamine Combination
Antitussive